IOF Positions and Statements

osteoporosis international, scientific peer-reviewed journal
A new review, endorsed by the International Osteoporosis Foundation (IOF) and the European Society of Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), provides a succinct summary of several failings of the recent guidelines of the American College of Physicians (ACP) on the treatment of low bone density and osteoporosis. Read more
A new expert consensus endorsed by the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) has reviewed the benefits and safety of dietary protein for bone health, based on analyses of major research studies. Read more
Experts from the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) regret the recent decision by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) to reject the marketing application for abaloparatide, a potential new treatment option... Read more
In a letter published recently in The Lancet, leading experts have drawn attention to potentially harmful guidance resulting from the recent National Institute for Health and Care Excellence (NICE) updated Technology Appraisal on bisphosphonate use in osteoporosis (TA464). Read more
The newly published clinical practice guidelines from the American College of Physicians (ACP) update the ACP’s 2008 recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women.1 The updated ACP guidelines, simplified to improve access by primary care physicians, emphasize the need for treatment Read more
A new Position Statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated by aromatase-inhibitors (AI) and outlines key management strategies to help prevent bone loss and related fractures. Read more
El documento, publicado conjuntamente por siete organizaciones europeas e internacionales, identifica los factores de riesgo de fractura en pacientes tratados con inhibidores de la aromatasa (IA), y describe las estrategias clave de manejo para ayudar a prevenir la pérdida ósea y fracturas relacionadas. Read more
Although progressive muscle loss is a natural part of ageing, sarcopenia is generally identified when muscle mass and muscle function falls below defined thresholds. Sarcopenia’s impact can be enormous as it affects mobility, balance, risk of falls and fractures, and overall ability to perform tasks of daily living. Given the ageing of populations worldwide, public health and clinical... Read more
Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year. Identifying low adherence to medication – a problem commonly seen with many chronic diseases – is a critical issue as it jeopardizes the efficacy of treatment, leaving... Read more
calcium supplement tablets
An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF) has reviewed the evidence for the value of calcium supplementation, with or without vitamin D supplementation, in healthy musculoskeletal ageing. Read more

Pages

Subscribe to IOF Positions and Statements